Dr. Reddy’s In Pact To Co-Develop Biosimilar Keytruda For Global Markets

Dr. Reddy’s Laboratories said it has signed a collaboration and licence agreement with Alvotech to co-develop, manufacture, and commercialise a biosimilar version of Keytruda (pembrolizumab) for international markets, the company said in an exchange filing.

Keytruda, a cancer immunotherapy drug, reported $29.5 billion in global sales in 2024. Dr. Reddy’s said the partnership will strengthen its position in oncology, with CEO Erez Israeli noting that pembrolizumab is among the most important therapies in immuno-oncology.